Erlotinib Completed Phase 2 Trials for Sarcomatous Mesothelioma / Recurrent Malignant Mesothelioma / Epithelial Mesothelioma / Advanced Malignant Mesothelioma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00039182Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung